Progen Co., Ltd.

Rani Therapeutics' Oral GLP-1/GLP-2 Capsule RT-114 Achieves Bioavailability Exceeding 150% of Subcutaneous Dose in Phase 1a Trial

- Oral RT-114 delivered via RaniPill Capsule achieved systemic exposure greater than 150% relative to a matched 12 mg subcutaneous dose of PG-102 in a 30-person Phase 1a study. - Elimination half-life was nearly identical between oral (5.6 days) and subcutaneous (5.3 days) arms, suggesting intact peptide delivery into systemic circulation. - No adverse events were attributed to the RaniPill Capsule device; treatment-related events were mild, transient, and consistent with the GLP-1/GLP-2 agonist class. - The Phase 1a study is being expanded with a 15-person cohort to further characterize dose-concentration relationships before a Phase 1b obesity study expected to begin in 2026.